Navigation Links
MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy

torical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the ‘Safe Harbor’ provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectation or forecasts of future events. MediQuest’s performance and financial results could differ materially from those reflected in these forward-looking statements due to the decisions of regulatory authorities, ability to implement its commercial plans, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally. For a discussion of these and other risks and uncertainties that may affect the forward-looking statements please contact the Company. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. MediQuest undertakes no obligation to update publicly any forward-looking statement.

# # #

Media Contacts:
Emily Zshornack-Topacio, MediQuest
Phone: 425-398-9580; E-mail: emily@mqti.com
Robert Gara, APCO Worldwide
Phone: 206-239-0111; E-mail: rgara@apcoworldwide.com



'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/6/2009)...E, Md., Jan. 6 Sequella... focused on diseases of epidemic potential, announ...the treatment of tuberculosis (TB), was the first ...inical program contract to Dynport Vaccine Company...arded by the National Institute of Allergy and Inf...
(Date:1/5/2009)...ESDA, Md., Jan. 5 Microm...ompany developing novel, proprietary,antibodies f...mmune diseases,provides an outlook on key events...t intends to provide an update on its research and..., -- April 12 to 16, 2009: Update on several ...
(Date:12/27/2008)...D,S, Bermuda, Dec. 23 Wa...today that one of its subsidiaries and Mayne Pharm...of Hospira, Inc., have filed lawsuits against each..., Mylan Pharmaceuticals Inc. ("Mylan") and Impax L... for the District of New Jersey for infringement o...
(Date:12/17/2008)...est, Most Complex of Its Kind; 80 Percent of Traum..., Dec. 17 A multi-disciplinary tea...ntly performed the first near-total face transpla...procedure performed within the past two weeks, sur...o suffered severe facial trauma -- essentially rep...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Six Positive Predictions for 2008 from SuperLife World Service 8518 1Six Positive Predictions for 2008 from SuperLife World Service 8518 2ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 1ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 2China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 1China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 2AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 1AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 2
...ce suggests that if you,could choose your parents,...ase. Researchers from the long-standing,Framingham...t,Lung, and Blood Institute (NHLBI) of the Nation...parents live longer were more,likely to avoid deve...other risk factors for cardiovascular disease in m...
...3, 2007 -,Cytos Biotechnology AG (SWX:CYTN) report...ith CYT003-QbG10, an immunotherapeutic,product can... study,included 40 patients suffering from mild to...lergy (hay fever). The trial,investigated in a dou...oratory efficacy of two different formulations of ...
Other Medicine Technology:Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 2Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
(Date:1/8/2009)...e introduces Senator Daschle at his confirmation h...n Services , , , WASHINGTON, Jan. 8 /PRNewswi...ounding board member Senator Tom Daschle, nominee ...ary, was introduced by fellow BPC founder and frie...day. The hearing was convened by the Senate Health...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)...lowered bad cholesterol more effectively than Zoco...-- After nearly a year of review, U.S. health offi...ued use of the controversial cholesterol-lowering ...ration said there was no significant difference in...Vytorin and patients taking the drug Zocor. , B...
(Date:1/8/2009)... local dance students will dance to raise money fo...IS, Jan. 8 , , , WHO: ...show off their talent in the 3rd annual Dance, ...ance Arts Centre. The, event will..., Participants raise money throu...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Dance With Courage to Benefit Camp Courage 2
...a steroid nasal spray to quash allergy symptoms ma...s say that when used on an "as-needed'', rather th...se) relieves// allergy symptoms such as runny nose...vely than the antihistamine loratadine (Claritin)....
...on of intravenous magnesium sulfate to standard em...amide, appears to reduce rather than enhance the e...olleagues from the Albert Einstein College of Medi...vidence that magnesium may be helpful in the treat...
...who smoke during pregnancy are more likely to bear...higher risk than others because of genetic suscept...determine the causes of low birth weight, though t...mmending at this point that women be screened for ...
... of Swiss researchers found that butterbur extract...fects. Mr John de Carpentier said,presumably it co... would not work - and therefore it is possible tha...ons. It was used in treating hayfever The researc...
Other Medicine News:
Aluminum Stylette 16 with Adjustable Stop.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Aluminum Stylette 16.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Medicine Products: